# Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study

> **NCT05441254** · PHASE2 · UNKNOWN · sponsor: **Zhongshan Hospital Xiamen University** · enrollment: 33 (estimated)

## Conditions studied

- Stage IV Gastric Cancer With Metastasis

## Interventions

- **DRUG:** Camrelizumab; Nab-paclitaxel; S-1

## Key facts

- **NCT ID:** NCT05441254
- **Lead sponsor:** Zhongshan Hospital Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07
- **Primary completion:** 2023-06
- **Final completion:** 2023-12
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2022-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05441254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05441254, "Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT05441254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*